| Clinical data | |
|---|---|
| Trade names | AiRuiYi |
| Other names | Fluzoparib; SHR3162 |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C22H16F4N6O2 |
| Molar mass | 472.404 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Fuzuloparib (trade nameAiRuiYi) is a pharmaceutical drug for the treatment ofovarian cancer.[1] It is approved for use in China.[2] It is aninhibitor of thepoly (ADP-ribose) polymerase (PARP) enzyme.[3]
It is also being studied for its potential use for the treatment ofpancreatic,breast,prostate, andlung cancer.[2]
Thisantineoplastic orimmunomodulatorydrug article is astub. You can help Wikipedia byexpanding it. |